uniQureQURE
QURE
About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Employees: 209
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
307% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $5.62M
43% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 37
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
7.1% more ownership
Funds ownership: 85.36% [Q4 2024] → 92.46% (+7.1%) [Q1 2025]
2% more funds holding
Funds holding: 137 [Q4 2024] → 140 (+3) [Q1 2025]
28% less capital invested
Capital invested by funds: $734M [Q4 2024] → $532M (-$202M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 3 (-3) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
83%
upside
Avg. target
$45
196%
upside
High target
$70
356%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Daniil Gataulin | 148%upside $38 | Buy Maintained | 30 May 2025 |
HC Wainwright & Co. Patrick Trucchio | 356%upside $70 | Buy Reiterated | 29 May 2025 |
Guggenheim Debjit Chattopadhyay | 83%upside $28 | Buy Reiterated | 12 May 2025 |
Financial journalist opinion
Based on 5 articles about QURE published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.
Neutral
GlobeNewsWire
1 week ago
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.
Positive
Seeking Alpha
2 weeks ago
uniQure's AMT-130 Gene Therapy Warrants An Upgrade
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough Therapy, RMAT, Fast-Track, and Orphan Drug status with Accelerated Approval via cUHDRS. Similarly, QURE is building MRI-guided infusion centers, payer-access teams, and a US Center of Excellence network. All of these moves prove management's high confidence in AMT-130.
Neutral
Zacks Investment Research
3 weeks ago
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Neutral
GlobeNewsWire
3 weeks ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?
The consensus price target hints at a 161.5% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Seeking Alpha
1 month ago
uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript
uniQure N.V. (NASDAQ:QURE ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director, Investor Relations Matt Kapusta - Chief Executive Officer Walid Abi-Saab - Chief Medical Officer Christian Klemt - Chief Financial Officer Conference Call Participants Luca Issi - RBC Debjit Chattopadhyay - Guggenheim Paul Matteis - Stifel Patrick Trucchio - H.C.
Negative
Zacks Investment Research
1 month ago
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
UniQure (QURE) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.36 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 ~ ~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of March 31, 2025 expected to fund operations into second half of 2027 ~ ~ uniQure to host inaugural earnings call at 8:30 a.m. ET ~ LEXINGTON, Mass.
Positive
Seeking Alpha
1 month ago
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phase 2 Huntington's Disease trial. I compare the data from these two treatments and share my thoughts here.
Charts implemented using Lightweight Charts™